|
Mon, 09/24/2018 - 02:42 |
Genentechs Investigational Medicine Entrectinib Showed a Durable Response of More Than Two Years in People With a Specific Type of Lung Cancer |
Genentech |
|
Tue, 09/04/2018 - 23:58 |
Genentech to Present New Data from Its Extensive Lung Cancer Program at the 2018 World Conference on Lung Cancer (WCLC) |
Genentech |
|
Thu, 11/16/2017 - 16:10 |
FDA expands approval of Sutent to reduce the risk of kidney cancer returning |
FDA |
|
Fri, 10/06/2017 - 09:50 |
FDA awards 15 grants for clinical trials to stimulate product development for rare diseases |
FDA |
|
Tue, 09/19/2017 - 09:27 |
Pfizer Announces Outcome of FDA Advisory Committee Meeting for SUTENT in Patients at High Risk of Recurrent Renal Cell Carcinoma after Surgery |
Pfizer |
|
Thu, 04/27/2017 - 11:57 |
FDA expands approved use of Stivarga to treat liver cancer |
FDA |
|
Tue, 11/29/2016 - 08:52 |
Dr. David Tuveson named Director, NCI-Designated Cancer Center at Cold Spring Harbor Laboratory |
CSHL |
|
Fri, 07/08/2016 - 06:24 |
Pfizer Announces Positive Top-Line Results From Phase 3 S-TRAC Trial of SUTENT (sunitinib) as Adjuvant Therapy in Patients at High Risk of Recurrent Renal Cell Carcinoma |
Pfizer |
|
Tue, 06/14/2016 - 14:03 |
Genomic Health Launches Oncotype SEQ Liquid Biopsy Mutation Panel |
Exact Sciences |
